Clinical and translational aspects of malignant B-cell lymphomas.
- Prosjektnummer
- 2016051
- Ansvarlig person
- Harald Holte
- Institusjon
- Oslo universitetssykehus HF
- Prosjektkategori
- Forskerstipend
- Helsekategori
- Cancer
- Forskningsaktivitet
- 4. Detection and Diagnosis, 5. Treatment Developement
Nei
Nei
Nei
Nei
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
Blood 2022 Mar 24;139(12):1863.
PMID: 34932792
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
N Engl J Med 2022 Feb 17;386(7):629. Epub 2021 des 14
PMID: 34904798
A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL.
Blood Adv 2021 11 23;5(22):4771-4782.
PMID: 34543384
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol 2021 10;22(10):1403-1415. Epub 2021 sep 10
PMID: 34516954
Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma.
Eur J Cancer 2021 11;157():132-139. Epub 2021 sep 8
PMID: 34508995
Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma.
Haematologica 2021 09 01;106(9):2502-2506. Epub 2021 sep 1
PMID: 33764002
Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma.
Cancers (Basel) 2021 Jan 22;13(3). Epub 2021 jan 22
PMID: 33499013
Sexual dysfunction is prevalent in female lymphoma survivors after autologous stem-cell transplantation and is associated with younger age, chronic fatigue, and mental distress.
Bone Marrow Transplant 2021 04;56(4):968-970. Epub 2020 nov 3
PMID: 33139869
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients.
Br J Haematol 2020 05;189(4):661-671. Epub 2020 feb 4
PMID: 32017050
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.
Blood Adv 2020 02 25;4(4):629-637.
PMID: 32074277
Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma.
Haematologica 2020 02 20. Epub 2020 feb 20
PMID: 32079690
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series.
Blood Adv 2020 05 12;4(9):1859-1866.
PMID: 32374878
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis.
Blood Adv 2020 05 12;4(9):1906-1915.
PMID: 32380536
The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy.
Br J Haematol 2020 May 14. Epub 2020 mai 14
PMID: 32410260
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
Blood Adv 2020 Sep 08;4(17):4091-4101.
PMID: 32877524
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med 2019 01 03;380(1):45-56. Epub 2018 des 1
PMID: 30501490
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.
Cancer Immunol Res 2019 03;7(3):355-362. Epub 2019 jan 18
PMID: 30659053
Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes.
Acta Oncol 2019 May;58(5):690-699. Epub 2019 jan 30
PMID: 30696346
Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study.
J Clin Oncol 2019 Mar 20;37(9):703-713. Epub 2019 feb 6
PMID: 30726176
Reply to M. Sorigue et al.
J Clin Oncol 2019 Mar 20;37(9):759-760. Epub 2019 feb 8
PMID: 30735430
A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.
Haematologica 2019 Oct;104(10):e460-e464. Epub 2019 mar 7
PMID: 30846496
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.
Blood Adv 2019 04 23;3(8):1230-1243.
PMID: 30979721
Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes.
Leukemia 2019 Nov;33(11):2662-2672. Epub 2019 jun 11
PMID: 31186494
Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion.
Blood Adv 2019 Jul 23;3(14):2230-2236.
PMID: 31332046
No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy.
Br J Haematol 2019 Oct 14. Epub 2019 okt 14
PMID: 31612478
Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation.
Bone Marrow Transplant 2020 05;55(5):891-905. Epub 2019 nov 19
PMID: 31745250
Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.
Blood 2018 Nov 29;132(22):2401-2405. Epub 2018 sep 26
PMID: 30257882
Efficacy of the Nordic and the MSKCC chemotherapy protocols on the overall and progression-free survival in intracranial PCNSL.
Blood Cells Mol Dis 2018 Nov;73():25-32. Epub 2018 aug 30
PMID: 30217760
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.
J Clin Oncol 2018 Oct 04. Epub 2018 okt 4
PMID: 30285560
The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.
Br J Haematol 2018 Oct;183(2):225-234. Epub 2018 aug 6
PMID: 30080252
The role of surgery in intracranial PCNSL.
Neurosurg Rev 2018 Oct;41(4):1037-1044. Epub 2018 jan 27
PMID: 29383600
Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity.
Bone Marrow Transplant 2019 04;54(4):607-610. Epub 2018 sep 27
PMID: 30262906
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.
Lancet Haematol 2018 Aug;5(8):e359-e367. Epub 2018 jul 4
PMID: 30078408
Pre-dosing with lilotomab prior to therapy with
Eur J Nucl Med Mol Imaging 2018 07;45(7):1233-1241. Epub 2018 feb 22
PMID: 29470615
Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?
Neuroradiology 2018 Jul;60(7):703-713. Epub 2018 mai 27
PMID: 29804159
Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation.
Acta Oncol 2018 Jun;57(6):773-781. Epub 2017 nov 24
PMID: 29171324
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate
J Nucl Med 2018 Apr;59(4):704-710. Epub 2017 aug 28
PMID: 28848035
Sample-Index Misassignment Impacts Tumour Exome Sequencing.
Sci Rep 2018 Mar 28;8(1):5307. Epub 2018 mar 28
PMID: 29593270
Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma.
Brain Behav 2018 03;8(3):e00928. Epub 2018 feb 5
PMID: 29541540
Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years.
Hematol Oncol 2018 Feb;36(1):217-223. Epub 2017 apr 9
PMID: 28393375
Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma.
Leuk Lymphoma 2017 Mar;58(3):623-632. Epub 2016 jul 7
PMID: 27389974
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.
J Nucl Med 2017 Jan;58(1):48-54. Epub 2016 aug 4
PMID: 27493270
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.
J Nucl Med 2017 Jan;58(1):55-61. Epub 2016 sep 1
PMID: 27587710
Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial.
Clin Microbiol Infect 2017 Mar;23(3):179-187. Epub 2016 okt 26
PMID: 27793737
Diffusing capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation.
Bone Marrow Transplant 2017 04;52(4):646-649. Epub 2016 des 19
PMID: 27991891
Bone mineral density is close to normal for age in long-term lymphoma survivors treated with high-dose therapy with autologous stem cell transplantation.
Acta Oncol 2017 Apr;56(4):590-598. Epub 2017 jan 12
PMID: 28077016
Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma.
Haematologica 2017 May;102(5):e195-e198. Epub 2017 feb 9
PMID: 28183850
New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.
J Clin Oncol 2017 May 20;35(15):1668-1677. Epub 2017 mar 14
PMID: 28291392
Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma.
Blood Cancer J 2017 Aug 25;7(8):e596. Epub 2017 aug 25
PMID: 28841210
MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma.
Blood Cancer J 2017 Dec 15;7(12):654. Epub 2017 des 15
PMID: 29242506
A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.
Br J Haematol 2016 May;173(3):432-43. Epub 2016 feb 23
PMID: 26914167
Valvular Dysfunction in Lymphoma Survivors Treated With Autologous Stem Cell Transplantation: A National Cross-Sectional Study.
JACC Cardiovasc Imaging 2016 Mar;9(3):230-9. Epub 2016 feb 17
PMID: 26897666
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Br J Haematol 2016 Jun;173(5):722-30. Epub 2016 mar 24
PMID: 27010483
Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation.
Acta Oncol 2016 May;55(5):547-53.
PMID: 27123741
The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
Br J Haematol 2016 Oct;175(1):102-14. Epub 2016 jun 24
PMID: 27341313
Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation.
Br J Cancer 2016 Jul 12;115(2):178-87. Epub 2016 jun 28
PMID: 27351215
Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study.
Blood Cancer J 2016 Nov 18;6(11):e501. Epub 2016 nov 18
PMID: 27858932
A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma
Med 3 Dec 2020
The DLBCL90 gene‐expression assay identifies double‐hit lymphomas with high sensitivity in patients from two phase II clinical trials with high‐risk diffuse large B‐cell lymphoma
eJHaem 05 Dec 2020
Stage I-II indolent non-Hodgkin’s lymphoma, mantle cell lymphoma and plasmacytoma;
- Disputert:
- august 2017
- Hovedveileder:
- Harald Holte
Hormonal dysfunction, fatigue and bone marrow density in cancer survivors
- Disputert:
- mars 2017
- Hovedveileder:
- Cecilie E. Kiserud
Clinical and immunohistochemical studies in B-cell lymphoma
- Disputert:
- juni 2017
- Hovedveileder:
- Erlend B Smeland
High dose therapy with autologous stem cell transplantation for lymphoma in Norway: utilisation and long-term effects.
- Disputert:
- oktober 2016
- Hovedveileder:
- Cecilie E. Kiserud
- Harald Holte Forsker (finansiert av denne bevilgning)
- Yngvild Nuvin Blaker Postdoktorstipendiat (annen finansiering)
- Marianne Brodtkorb Eide Prosjektdeltaker
- Kathrine Thuesta Isaksen Doktorgradsstipendiat (annen finansiering)
- Erlend B Smeland Prosjektdeltaker
- Ola Myklebost Prosjektdeltaker
- Bjørn Østenstad Prosjektdeltaker
- Sirpa Leppä Prosjektdeltaker
- Eva Kimby Prosjektdeltaker
- Jillian Wise Postdoktorstipendiat (annen finansiering)
- Baoyan Bai Postdoktorstipendiat (annen finansiering)
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport